RecruitingPhase 3NCT07375563
Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma
Studying Ganglioneuroblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- Principal Investigator
- Tatyana V Shamanskaya, MD, PHDDmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
- Intervention
- Dinutuximab beta, temozolomide, irinotecan, autologous NK cell(combination_product)
- Enrollment
- 5 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (1)
- National medical research center of pediatric haematology, oncology and immulogy named after Dmytriy Rogachyov, Moscow, 117198, Moscow, Russia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07375563 on ClinicalTrials.govOther trials for Ganglioneuroblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07502287Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory NeuroblastomaBeijing Biotech
- RECRUITINGPHASE3NCT06172296Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk NeuroblastomaNational Cancer Institute (NCI)
- RECRUITINGNANCT05192980SIOPEN BIOPORTAL, An International Registry Linked to a Virtual Biobank for Patients With Peripheral Neuroblastic TumoursInstitut Curie
- RECRUITINGNCT06296732Abdominal Neuroblastoma Laparoscopic Surgery Risk Factors StratificationFederal Research Institute of Pediatric Hematology, Oncology and Immunology
- RECRUITINGPHASE3NCT06071897Induction Chemoimmunotherapy for Patients With High-risk NeuroblastomaFederal Research Institute of Pediatric Hematology, Oncology and Immunology
- ACTIVE NOT RECRUITINGPHASE2NCT04385277Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)Children's Oncology Group
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT04040088An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine TumorsMayo Clinic
- ACTIVE NOT RECRUITINGPHASE2NCT03786783Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk NeuroblastomaNational Cancer Institute (NCI)